Meet the challenge in the busy work
Release time:
2020-08-14
Meeting Challenges in Busy Work
Pharmaceutical Company 2017 Outstanding Scientific and Technological Workers Pharmaceutical Company Central Laboratory Han Ying
With the overall deepening of the national medical reform policy, 2017 is a challenging year for us as a member of the central laboratory, I also have a deep feeling that in the past year, the laboratory has been busy, tense and challenging.
Over the past year, the central laboratory has conscientiously performed its duties of GMP , made great efforts to improve its technical service capability, and completed daily testing of 683 batches of finished products (including 123 batches of Qiubin Factory and 560 batches of Jinxi Factory), 658 batches of raw materials and packaging materials, 1271 batches of process water; batches of intermediates, 538 batches of stability inspection products; Participated in more than ten process verification inspections, involving hundreds of samples; Completed the environmental monitoring work of 1102 batch of Jinxi Pharmaceutical Factory.
There are many new products in the past year. Inspection method confirmation and process verification should be done for new products. Faced with the situation of tight time, heavy tasks and insufficient personnel and instruments, all the laboratory staff did not flinch, faced up to the difficulties, overcame the difficulties, and successfully completed the inspection method verification and process verification of esomeprazole sodium, deoxypodophyllotoxin for injection and other products and related raw and auxiliary materials, totaling about 50 method confirmation.
My main job in the central laboratory is to assist the director to carry out departmental work and to be in charge of the laboratory raw material group. In order to play a good role in the post, do a good job in auxiliary work and manage the raw material group, I often go to various posts to understand the working conditions and be familiar with the testing instruments and the operation process of relevant posts.
raw material group involves many varieties, each batch of raw materials, chemical raw materials and packaging materials into the factory, need to be timely inspection, to ensure that qualified. In order to carry out the work of the raw material group smoothly, while assisting the department director, I have carried out reasonable division of labor and strict requirements on the personnel of the raw material group, and strengthened the maintenance and calibration of instruments.
I also attach great importance to the training of team members to improve their skills. In daily work, when there is a sudden failure of the inspection instrument, I will analyze the cause as soon as possible, solve it in time, ensure the normal inspection work, sum up experience, and learn and improve together with the staff.
Looking back over the past year, the reason why the central laboratory has been able to overcome various difficulties and successfully complete the company's inspection tasks is that we have continuously focused on management, process, detailed work, improved various rules and regulations, tapped the potential of employees, changed employees' working ideas , , strengthened theoretical study, attached importance to training, and improved the overall quality of the team. "Unity and struggle, truth-seeking and innovation, determination to rise to the top and climb the peak forever" is our enterprise spirit. "Pragmatic innovation, steady behavior, standardized management and strong implementation" is the work style of our enterprise. Under the guidance of this spirit and style, I will continue to work hard and make persistent efforts to live up to the love of leaders and colleagues. (According to Han Ying's speech at the summary and commendation meeting of pharmaceutical companies)
More information
Publicity of Environmental Protection Acceptance for Completion of Kiln End Flue Gas Desulfurization Project of daye peak cement co., ltd. According to the requirements of the Interim Measures for Environmental Protection Acceptance for Completion of Construction Projects (No.4 [2017] of the State Environmental Regulations) issued by the Ministry of Environmental Protection, the environmental protection acceptance information of "Kiln End Flue Gas Desulfurization Project" of daye peak cement co., ltd. is now publicized. Basic Information of 1. Project Project Name: Kiln End Flue Gas Desulfurization Project Construction Unit: daye Jianfeng Cement Co., Ltd. Project Construction Location: Yongguang Village, Baoan Town, daye city, nature of the project in the existing plant area of daye Jianfeng Cement Co., Ltd.: The construction content of the technological transformation project is: This technological transformation project is mainly to build a wet desulfurization system for kiln end gas of the company's existing 4000t cement clinker production line, adopting limestone-gypsum wet flue gas desulfurization process. The project covers a total area of 500 m2, with a new construction area of about 450 m2. It mainly builds desulfurization complex building, flue gas system, SO2 absorption system, limestone powder conveying and limestone slurry preparation system, process water system, gypsum dehydration system and supporting pipelines. Power supply, water supply, compressed air and other public works rely on the existing plant. Total investment and environmental protection investment: the total investment of the project is 10.37 million yuan, all of which are environmental protection investment. The project was entrusted to Huangshi Yangtze River Environmental Engineering Design and Research Institute to carry out environmental impact assessment in September 2017. On November 16, 2017, Daye Municipal Environmental Protection Bureau issued a reply with YEHAN [2017] No. 354. Implementation of 2. environmental protection measures The scope of this acceptance is the flue gas desulfurization system and supporting facilities at the end of the kiln. (1) Exhaust gas pollution
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Contact Us
No. 88 Wujiang East Road, Jinhua City, Zhejiang Province, China
Tel: +86-579-82326868
Fax : +86-579-82324666
©2023 Zhejiang Jianfeng Group Co., Ltd. Powered by: www.300.cn SEO Business License
SAF Coolest v1.2 设置面板 SHJSS-AHDB-FSSQE-ZSW
无数据提示
Sorry, the current column has no content !
You can view other columns or return to Home Page